Hepatocellular carcinoma cell-specific peptide ligand for targeted drug delivery
Open Access
- 1 March 2008
- journal article
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Therapeutics
- Vol. 7 (3), 579-589
- https://doi.org/10.1158/1535-7163.mct-07-2359
Abstract
Hepatocellular carcinoma is the fourth leading cause of cancer death worldwide. Novel treatment strategies derived from increased knowledge of molecular oncology are constantly being developed to cure this disease. Here, we used phage display to identify a novel peptide (SP94), which binds specifically to hepatocellular carcinoma cells. In vitro, the phage clone PC94 was shown to bind to hepatocellular carcinoma cell lines by ELISA and flow cytometry analysis. In vivo, PC94 homed specifically to tumor tissues but not to normal visceral organs in severe combined immunodeficient mice bearing human hepatocellular carcinoma xenografts. This homing ability could be competitively inhibited by synthetic peptide, SP94. Immunohistochemical staining confirmed that PC94 localized to tumor tissues and that it could not be detected in SP94-competed tumor tissues. In addition, PC94 recognized the tumor tissue but not nontumor tissue in surgical specimens from hepatocellular carcinoma patients, with a positive rate of 61.3% (19 of 31). With the conjugation of SP94 and liposomal doxorubicin, the targeted drug delivery system enhanced the therapeutic efficacy against hepatocellular carcinoma xenografts through enhanced tumor apoptosis and decreased tumor angiogenesis. Our results indicate that SP94 has the potential to improve the systemic treatment of patients with advanced hepatocellular carcinoma. [Mol Cancer Ther 2008;7(3):579–89]Keywords
This publication has 35 references indexed in Scilit:
- Peptide-Mediated Targeting to Tumor Blood Vessels of Lung Cancer for Drug DeliveryCancer Research, 2007
- Generation and Characterization of Monoclonal Antibodies against Dengue Virus Type 1 for Epitope Mapping and Serological Detection by Epitope-Based Peptide AntigensClinical and Vaccine Immunology, 2007
- Hepatocellular carcinoma pathogenesis: from genes to environmentNature Reviews Cancer, 2006
- The clinical benefit of pegylated liposomal doxorubicin in patients with metastatic breast cancer previously treated with conventional anthracyclines: a multicentre phase II trialBritish Journal of Cancer, 2006
- Enhanced intracellular delivery and improved antitumor efficacy of doxorubicin by sterically stabilized liposomes modified with a synthetic RGD mimeticJournal of Controlled Release, 2005
- A Novel Peptide Specifically Binding to Nasopharyngeal Carcinoma For Targeted Drug DeliveryCancer Research, 2004
- Identification of a dengue virus type 2 (DEN-2) serotype-specific B-cell epitope and detection of DEN-2-immunized animal serum samples using an epitope-based peptide antigenJournal of General Virology, 2003
- Identification of novel carrier peptides for the specific delivery of therapeutics into cancer cellsThe FASEB Journal, 2002
- Phase I and pharmacokinetic study of a stable, polyethylene-glycolated liposomal doxorubicin in patients with solid tumorsCancer, 2001
- Doxorubicin Encapsulated in Liposomes Containing Surface‐Bound Polyethylene Glycol: Pharmacokinetics, Tumor Localization, and Safety in Patients with AIDS‐Related Kaposi's SarcomaThe Journal of Clinical Pharmacology, 1996